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Abstract Chronic lymphocytic leukemia (CLL) is unique
among B cell malignancies in that the malignant clones can
be featured either somatically mutated or unmutated IGVH
genes. CLL cells that express unmutated immunoglobulin
variable domains likely underwent final development prior
to their entry into the germinal center, whereas those that
express mutated variable domains likely transited through
the germinal center and then underwent final development.
Regardless, the cellular origin of CLL remains unknown.
The aim of this review is to summarize immunological
aspects involved in this process and to provide insights
about the complex biology and pathogenesis of this disease.
We propose a mechanistic hypothesis to explain the origin
of B-CLL clones into our current picture of normal B cell
development. In particular, we suggest that unmutated CLL
arises from normal B cells with self-reactivity for apoptotic
bodies that have undergone receptor editing, CD5 expression,
and anergic processes in the bone marrow. Similarly, mutated
CLL would arise from cells that, while acquiring self-
reactivity for autoantigens—including apoptotic bodies—in
germinal centers, are also still subject to tolerization mecha-
nisms, including receptor editing and anergy. We believe that
CLL is a proliferation of B lymphocytes selected during clonal
expansion through multiple encounters with (auto)antigens,
despite the fact that they differ in their state of activation and
maturation. Autoantigens and microbial pathogens activate
BCR signaling and promote tolerogenic mechanisms such as
receptor editing/revision, anergy, CD5+ expression, and somat-
ic hypermutation in CLLB cells. The result of these tolerogenic
mechanisms is the survival of CLL B cell clones with similar
surface markers and homogeneous gene expression signatures.
We suggest that both immunophenotypic surface markers and
homogenous gene expression might represent the evidence of
several attempts to re-educate self-reactive B cells.
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Introduction
Chronic lymphocytic leukemia (CLL) includes cases featur-
ing somatically mutated or unmutated immunoglobulin
heavy variable genes (IGVH). The former consist of cells
that likely transited through the germinal center and then
underwent final transformation, while the latter consist of
cells that likely underwent final transformation prior to their
entry into the germinal center. Be as it may, the cellular
origin of CLL remains unknown. However, recent advances
in our knowledge of CLL biology suggest that CLL results
from a proliferation of B lymphocytes selected during clonal
expansion through multiple encounters with (auto) antigens,
despite the fact that they differ in their state of activation and
maturation. The aim of this review is to summarize immu-
nological aspects involved in this process and to provide
insights about the complex biology and pathogenesis of this
disease. As such, we will discuss the potential harmful steps
during the development of lymphocytes, as well as tolerance
checkpoints (anergy, deletion, germinal centre exclusion,
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receptor editing and revision, memory checkpoints, and so-
matic hypermutation) and immune responses that induce the
development and proliferation of neoplastic lymphocytes.
We propose a mechanistic hypothesis to explain the
origin of B-CLL clones into our current picture of normal
B cell development. In particular, we suggest that unmutated
CLL arises from normal B cells with self-reactivity for
apoptotic bodies that have undergone receptor editing,
CD5 expression and anergic processes in the bone marrow.
Similarly, mutated CLL would arise from cells that while
acquiring self-reactivity for autoantigens—including apoptotic
bodies—in germinal centers are also still subject to tolerization
mechanisms, including receptor editing and anergy.
Definition
CLL is the most common form of leukemia in adults and
presents with progressive accumulation of B cells in the
blood, bone marrow, and lymphatic tissue. When the disease
involves the peripheral blood and bone marrow, it is called
CLL, while when lymph nodes or other tissues are infiltrated
by cells with identical morphologic and immunophenotypic
features to CLL, and yet leukemic manifestations of the dis-
ease are absent, it is called small lymphocytic lymphoma. In
the World Health Organization classification, the two entities
are now considered simply as different clinical manifestations
of the same disease.
Diagnosis of CLL
The diagnosis of CLL requires the presence of at least 5,000
B lymphocytes per microliter in the peripheral blood [1].
Flow cytometry studies performed in patients with leukemic
cells include kappa/lambda ratio to assess clonality. The
defining feature of the B-CLL clone is the co-expression
of CD19, CD20, CD5, and CD23. The levels of surface
immunoglobulin, CD20, and CD79 are characteristically
low compared to those found on normal B cells [2]. Bone
marrow involvement is typically pronounced, with more
than 30 % of the nucleated cells in the aspirate being of
lymphoid origin.
Prognostic markers in CLL
Several prognostic factors are currently used for risk assess-
ment prior to the beginning of standard treatment in CLL.
For instance, about 50 % of patients with CLL present
leukemic cells with somatic hypermutation in rearranged
immunoglobulin heavy-chain variable region genes, and
they tend to have a more favorable outcome than the other
half. The definition of mutated or unmutated CLL is based
on an arbitrarily defined threshold of 98 % homology to the
most similar germline gene. Overall, the high-risk pheno-
type is typically associated to unmutated immunoglobulin
heavy variable genes [3], expression of the CD38 surface
marker [4] and the zeta-associated protein 70 (ZAP-70) [5],
as well as to chromosomal aberrations such as 17p (the site
of tumor protein p53) or 11q23 deletions (the site of ataxia
telangiectasia mutated ATM) [6]. Low-risk phenotype habit-
ually features mutated IGVH, lacks CD38 and ZAP-70, and
displays a normal karyotipe or 13q14 deletion. Additional
adverse predictive factors include advanced Rai [7] and Binet
clinical stage [8], usage of VH3-21 independently on the VH
mutation status [9], and short lymphocyte doubling time [10].
These factors predict differences in time to disease progres-
sion, time to first treatment, and response to therapy [11].
Development of B cell repertoire
B cell development occurs initially in the bone marrow and
subsequently in lymphoid organs. Later, terminal B cell
differentiation also takes place in the bone marrow. In the
first step of the whole process, hematopoietic progenitor
cells (HSC) differentiate into the earliest identifiable cell
type committed to the B cell lineage, the pro-B cell. Inter-
estingly, HSCs of patients with CLL have an increased
capacity for generating large numbers of pro-B cells, which
undergo clonal selection and ultimately lead to a monoclo-
nal B cell lymphocytosis and then to chronic lymphocytic
leukemia B cells [12]. The pro-B cell undergoes a rearrange-
ment of its immunoglobulin (Ig) heavy-chain genes, features
cytoplasmic μ chains, and is now called pre-B cell. Subse-
quent rearrangement of the light chain enables the cell to
express surface IgM, thereby becoming an immature B
lymphocyte. These cells leave the bone marrow and, on
entering the peripheral blood, start to express surface IgD,
being now called naïve B cells. They are arrested in the G0
phase of the cell cycle and enter the lymphoid tissue, where
they are exposed to antigen-presenting cells, become acti-
vated, and differentiate into plasma cells or memory B cells.
The memory B cells travel from the extra-follicular area of
the lymph node to the primary follicles, where they are
confronted with an antigen presented by follicular dendritic
cells, resulting in the triggering of a secondary immune
response. At this stage, primary follicles change into second-
ary follicles containing germinal centers. Through activation
by an antigen, memory B cells differentiate into centroblasts,
resulting in Ig isotype switching and somatic mutations in the
variable region of the Ig with the generation of high-affinity
antibodies. Centroblasts then progress to the centrocyte stage
and re-express surface Ig. The centrocytes with high-affinity
antibodies differentiate into either memory B cells or
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plasmablasts, which subsequently move to the bone marrow
and terminally differentiate into plasma cells.
Intriguingly, it is not certain at what stage in lymphocyte
maturation CLL arises, since roughly equal numbers seem
to originate from a pre- and post-germinal center B lymphocyte
[3]. Analyses of immunoglobulin genes and gene expression
patterns have defined at least two types of CLL that differ in
their tendency towards disease progression: one arises from
relatively less differentiated (immature?) B cells with unmu-
tated heavy-chain genes and has a poor prognosis; the other
evolves from more differentiated (memory type) B cells with
somatically mutated heavy-chain genes and has a good prog-
nosis [13].
B cell tolerance checkpoints
Tolerance can be mediated by mechanisms that operate at
multiple checkpoints throughout B cell development, includ-
ing clonal anergy, clonal deletion, and receptor editing
[14–16]. At an immature B cell developmental stage, B cell
receptor (BCR) signaling mediates a remarkable diversity of
cellular responses, including developmental progression or
arrest, change in location within peripheral lymphoid tissues,
survival or apoptosis, and proliferation. During the course of
ontogenesis, B cells mature in the bone marrow according to
the evolution of Ig chain synthesis. Starting with the rear-
rangement of VDJ genes for the heavy chain at the pre-B
stage, the recombination process continues through the VJ
gene rearrangements for kappa or lambda light chain at the
immature stage. Thus, the resulting BCR, comprised of ran-
domly selected heavy and light chains, has an unpredictable
specificity that could include the ability to “self” bind. If an
immature B cell in the bone marrow is not self-reactive, it can
leave the bone marrow and transit to the periphery and spleen,
where it is called transitional B cell [17]. B cells with reactivity
to self-antigens generate moderate to high levels of BCR
signaling, which induces biological responses promoting immu-
nological tolerance in the B cell compartment. If an immature B
cell binds well to self-antigens, then the resulting BCR signaling
causes maturation arrest; however, self-reactive B cells may
evade death by switching their heavy- or light-chain expression
so as to avoid self-reactivity, a process called receptor editing
[18–21]. Self-reactive transitional cells begin the receptor edit-
ing process like immature B cells in the bone marrow, but die
due to the lack of protective signals provided to immature B
cells by bone marrow stromal cells [22]. Similar to immature B
cells, CLL cells need survival signals provided by nurse-like
cells, cytokines or T cell-related molecules to elude apoptosis
[23–25].
It is important to note that autoreactive B cells may
undergo receptor editing and anergy in the bone marrow.
At the same time, recent evidence shows that light-chain
receptor editing occurs not only in bone marrow to cells
with a pre-B/immature B cell phenotype, but also in imma-
ture/transitional splenic B cells. Nevertheless, editing at the
heavy-chain locus appears to occur exclusively in bone
marrow cells with a pro-B phenotype [21].
Notably, CLL B cells express CD5 as a surface marker.
CD5 cells have been described as a safeguard against auto-
immunity and a shield for cancer cells [26].
The specific role of CD5 and IL-10 in protection from
autoimmunity has been demonstrated in vivo. The HEL/
anti-HEL model is widely used to assess B cell tolerance.
In these mice, most B cells express a transgene encoding a
receptor for the T-dependent antigen hen egg lysozyme
(HEL). Since HEL is artificially expressed in these mice, it
is seen as a self-antigen. B cells thus meet their cognate
antigen during development, yet fail to be deleted and
instead become anergic to HEL and express CD5 [27].
The role of CD5 in the induction of anergy was demonstrat-
ed in an elegant experiment where double (HEL and BCR)
transgenic mice were bred into a CD5-null background [28].
By contrast to CD5+ animals, these mice developed hemo-
lytic anemia and responded strongly to HEL [28]. This
demonstrates that CD5 is necessary to maintain anergy in
B cells, thereby inducing self-tolerance. Interestingly, in
double-transgenic mice models responding to a T-dependent
antigen, HEL and its specific BCR, B cells express CD5 as a
result of repeated encounters with their own antigen [27].
Despite most CD5+CD19+ B cells are naïve and repre-
sent either transitional B cells or B1 cells that are able to
respond to T-independent antigens, a sizeable fraction (up to
25 %) of CD5+ B cells in the blood co-express the memory-
associated molecule CD27 [29, 30] suggesting that CD5 is
an activation marker. Importantly, CD5 could be induced on
B cells in vitro. The optimal activating conditions require
simultaneous stimulation of both BCR and CD40 surface
molecules [29, 31, 32], although IL-6 [31] and the polyclon-
al activator Staphylococcus aureus Cowan Strain (SAC)
[33] also stimulate CD5 expression on B cells. For these
reasons, CD5 is a marker of some T1/B1 B cells but can also
be induced on B2 B cells, indirectly supporting the idea that
the origin of CD5+ leukemic B cells could be from self-
reactive B cells and not a lineage-specific B cell.
Essentially, CD5 expression maintains tolerance in aner-
gic B cells [28], inhibits early BCR signaling events [34],
induces IL-10 secretion in B cells [29] and is associated with
receptor editing/revision outside germinal centers [35]. Nota-
bly, activation of CD5-negative naïve mature B cells by anti-
IgM plus CD40 induces expression of CD5 on a subset of
cells, and leads to the upregulation of RAG1 and RAG2 only
in cells turned positive for CD5 [35]. This piece of evidence,
together with the fact that receptor editing/revision attempts to
avoid autoimmunity, suggests that auto-reactive B cells could
express CD5+ when their BCRs recognize auto-antigens.
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There are also data showing that regulatory checkpoints
exist for B cells in the periphery of the germinal center and
at the late stages of B cell differentiation into memory or
long-lived plasma cells [36, 37]. Germinal center exclusion
of self-reactive B cells (9G4 B cells) that express self-
reactive antibodies encoded by the IGVH 4-34 gene is an
important peripheral checkpoint to avoid the interaction of
autoreactive B and T cells, with the subsequent generation
of autoantibodies. For this reason, 9G4 B cells only account
for 5–10 % of the naïve B cell repertoire in healthy donors,
as well as in the IgM memory compartment, and these cells
can be found in less than 1 % of germinal centers in tonsil
biopsies [36, 38]. Preventing the generation of self-reactive
memory B or long-lived plasma cells is another important
peripheral checkpoint to avoid autoimmunity. B cells
expressing self-reactive and broadly bacterially-reactive
antibodies are continuously removed from the repertoire in
the transition from naïve to IgM memory B cells, and
selection against self-reactive antibodies is implemented
before the onset of somatic hypermutation [39].
Cellular origin of CLL
As mentioned before, CLL cells that express unmutated im-
munoglobulin variable domains are those that likely underwent
final development prior to their entry into the germinal center,
whereas those that express mutated variable domains likely
transited the germinal center first and then underwent final
transformation. Regardless, the cellular origin of CLL remains
unknown.
1. Marginal zone B cells as the origin of CLL
Chiorazzi and Ferrarini suggest that CLL derives from
competent B lymphocytes selected for clonal expansion and
eventual transformation by multiple encounters and responses
to (auto)antigen(s). The observation that the CLL cell surface-
marker phenotype (CD5+CD23+CD27+low Igs) does not
resemble that of any known normal B cell and that both
mutated and unmutated cases show homogenous gene expres-
sion signatures with only minor differences [40, 41] has
generated a unifying, parsimonious theory according to which
CLL clones with either mutated or unmutated IGVHs derive
from marginal zone B cells [42]. The authors take advantage
of features of marginal zone B cells to explain the origin of
CLL. Marginal zone B cells can respond to T-independent as
well as T-dependent antigens [43], can display activated mem-
brane phenotypes [44–46] after antigens encounter, and express
B cell receptors by unmutated and mutated IGV genes [47, 48].
Interestingly, marginal zone B cells are now seen as major
players at the interface between the initial innate and the
delayed adaptive immune response [49].
A typical feature of marginal zone B cells is their capacity to
respond to polysaccharide antigens [50]. The ability of
marginal zone B cells to respond rapidly and encapsulate
bacteria by differentiating into antigen-specific plasma cells
helps keeping such infections under control.
However, themain arguments against amarginal zone origin
of CLL are:
(a) differences in cell surface phenotype [42],
(b) the fact that marginal zone lymphomas usually express
VH1-2 [51] (but biases in VH1-69 and VH4-34 have also
been reported) [52],
(c) and that even in stage 0, patients with CLL have very
poor responses to vaccines. Protein vaccines have pro-
duced weak-to-moderate responses in up to 50 % of
patients, mainly in early-stage disease with normal se-
rum Ig levels, but responses to polysaccharide vaccines
have been virtually zero.
Importantly, marginal zone lymphocytes are a hetero-
geneous population of B cells. Despite this, it is possible
that some cases of CLL derive from marginal zone
B cells that up-regulate CD5 expression after an
encounter with either a self-antigen or a super-
antigen [33] and escape both central and peripheral
tolerance by several mechanisms that include muta-
tions in MYD88 [53, 54].
2. Human B1 cells
In a very recent article, Griffin et al. [55] have identified
the phenotype of human B1 cells. Surprisingly, several
similarities between normal human B1 cell and the
unmutated B cell subset have been discussed. Both are
CD20+CD27+CD43+CD70−, most normal B1 cells express
CD5, as do malignant CLL cells, and both express ZAP-70
and ILT3 [55]. The authors suggest that the chronically-
activated phenotype of normal B1 cells may predispose to
malignant transformation [55]. An argument against human
B1 cells as the origin of CLL is the fact that their CDR3 length
is inferior to that observed in CLL B. Moreover, B1 cells use
different IGHV from those observed in CLL B cells. However,
it is possible that during their development, some B1 cells
progress to leukemic B cells and, as such, may represent the
origin of unmutated CLL B cells [55].
3. Transitional B cells
B cells that leave the bone marrow need to reach the
splenic environment in order to complete their maturation
process. Immigrant maturing B cells pass through two tran-
sitional stages, known as transitional stage 1 (T1) and 2
(T2). Only a minority of these cells will successfully com-
plete the transition, as this differentiation step is a
crucial checkpoint for controlling self-reactivity. Passage
through this checkpoint requires the interaction of solu-
ble B cell-activating factor, a member of the tumor
necrosis factor family (BAFF), with its receptor BAFF-
R, which is primarily expressed on B cells [56].
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Chiorazzi and Ferrarini argue against transitional B
cells as the single source of CLL because these cells
express CD10, which is not to found on CLL cells
unless they have undergone apoptosis. However, the
absence of CD27, which is consistently found in CLL,
the lack of responsiveness to BAFF/BlyS/TALL-1 [42],
the recent discovery of mutations in MDY88 in CLL patients
[53], and their role in tolerance in CD19+CD10+IgM+CD27-
new emigrant B cells [54] raise the possibility that transitional
cells could be the origin of CLL B cells in some cases.
Pathogenesis and biology of CLL B cells
Although CLL is caused by the accumulation of neoplastic
lymphocytes in the G0 phase of the cell cycle, some studies
have demonstrated that a proportion of neoplastic CLL
lymphocytes, ranging between 0.1 and 1 % per day, are
actively duplicating. Furthermore, patients with prolifera-
tion rates greater than 0.35 % per day have been found to
have a more aggressive disease [57, 58]. The analysis of
lymphoid tissues involved in CLL has revealed focal, scat-
tered aggregates of large, proliferating leukemic cells that
form nodular areas in lymph nodes and bone marrow [23, 59].
Numerous CD4+CD40L+T cell infiltrates are found in close
contact with the proliferating CLL cells [60], and micro-
environmental interactions with bone marrow stromal cells
are able to extend the survival of CLL upon direct contact
[59]. Thus, the CLL population may originate from a clone
with few or no V- domain mutations, or from a more mature
clone whose V domains have undergone the hypermutation
process. This creates two separate pools of B cells, both of
which originate from antigen-stimulated B lymphocytes.
CLL is now viewed as a proliferation of B lymphocytes
selected by clonal expansion throughmultiple encounters with
(auto) antigens, despite the fact that they differ in their state of
activation andmaturation. However, the fact that bothmutated
and unmutated CLL B cells recognize autoantigens [61, 62],
differing from each other by relatively few expressed genes
[41], and have stigmas suggesting that they have been re-
educated to avoid self-reactivity [29, 61, 63–76], suggests that
CLL is originated by a coordinated normal immunologic
tolerance mechanism to destroy self-reactive B cells. For these
reasons, we believe that CLL B cells are made, not born.
What is the role of central tolerance mechanisms in the
promotion of CLL B cell development? In an elegant series
of papers, Nemazee and coworkers have demonstrated that
two mechanisms of immune tolerance are used within the
bone marrow when immature B cells encounter self-
antigens and that the mechanism employed depends on the
state of maturation of the B cell. The first mechanism used
to confer B cell tolerance is referred to as receptor editing. If
an immature, self-reactive B cell encounters a self-antigen in
the bone marrow, the process promotes rearrangement of the
second immunoglobulin receptor light chain in the hope of
altering BCR specificity. In one study, two thirds of autor-
eactive immature B cells were found to undergo receptor
editing without any significant apoptosis [77]. Another
study found that later in B cell development, that is after
receptor editing has occurred, immature B cell engagement
with self-antigens leads to apoptosis within the bone mar-
row [78]. Intriguingly, receptor editing and receptor revision
may have undesirable consequences. Once a heavy chain
contributes in a dominant fashion to self-reactivity, a switch
in an antibody’s light chain may not fully abrogate autor-
eactivity. For this reason, receptor editing does not neces-
sarily result in the correction of autoreactivity, and might
influence the formation of polyreactive B cell receptors
[79–81]. In addition, the edited antibody will usually
have a longer CDR3, which in itself may predispose it
to autoreactivity or polyreactivity [79]. This could explain the
greater level of polyreactivity and autoreactivity of unmutated
CLL cells, as well as the reason for antibodies produced from
mutated CLL rearrangements can display polyreactivity after
their IGHVs are reverted to the germline sequence [61, 82].
Evidence of receptor editing in CLL B cells
The information relating to the receptor editing process,
which is involved in the control of self-reactive CLL B cells
that recognize autoantigens [61] and secrete autoantibodies
under stimulation [83], is supported by the following
observations:
(a) The significant role of immunoglobulin light chains in
antigen recognition and selection in CLL [64]. This
observation suggests that CLL cells are in active, (au-
to)antigen-driven receptor editing process.
(b) Both CLL subsets can express unusually long
HCDR.[65] This supports that CLL cells have edited
receptors.
(c) A subset of CLL patients have leukemic B cells that
express more than one functional Ig heavy chain [66],
suggesting that this lack of allelic exclusion could be
related to the receptor editing/revision process.
The fact that stereotypical CLL BCRs recognize autoan-
tigens in stromal cells [84] is an example of a situation
where receptor editing could be in a position to try to avoid
autoimmunity in a definite microenvironment. Interestingly,
79.3 % of unmutated CLL antibodies are polyreactive [61],
and reactivity with a particular form of apoptotic cells is a
common feature of this subset [62]. Intriguingly, the unmu-
tated CLL subset expresses antibodies with long heavy and
light-chain CDR3 [61]. Moreover, some cases of CLL have
multiple light-chain rearrangements [64], a feature that
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could imply receptor editing/revision and advocate that CLL
leukemic B cells undergo receptor editing to avoid
autoimmunity.
Some illustrative examples of receptor editing in CLL
include a number of cases that express lambda light chains
with either potentially functional IGKV1-17 gene rearrange-
ment [64], which has been associated with the cationic
charge of autoantibodies in lupus nephritis [85], or stereo-
typed IGHV3-21 CLL cases, which are characterized by a
strikingly biased expression of lambda light chains [64, 86,
87]. In addition, lambda chains are more efficient at silenc-
ing autoreactive/polyreactive antibodies than kappa chains
in humans [43]. Importantly, the light-chain rearrangements
of IGHV3-21 CLL cells have followed the hierarchical
pattern of light-chain recombination (IgK, IgK, and IgL) and
have undergone several attempts of rearrangement before
producing a functional light chain [64, 86, 87].
At this point in the discussion, we believe that subset recep-
tor editing fails to abrogate autoreactivity or polyreactivity in
the unmutated CLL; however, in some mutated CLL subsets,
receptor editing/revision has successfully worked to avoid self-
reactive BCRs.
Despite these arguments, the current hypothesis is that
mutated cases avoid autoreactivity by somatic mutations,
not by receptor editing mechanisms. This is supported by
the observation that biased mutations in the heavy and light
chains could diminish the responsiveness of CLL progeni-
tors to autoantigens [88]. The IGHV4-34/IGKV2-30 CLL
stereotype is characterized by “long” positively-charged
HCDR3 enriched in aromatic and positively-charged amino
acids, similar to pathogenic anti-DNA antibodies.[89] How-
ever, the fact that IGHV4-34 sequences should undergo
somatic hypermutation in order to negate their autoreactiv-
ity, and that the introduction of even a few strategically
positioned aspartic acid residues in the kappa chains of the
transgenic animals may be sufficient to abrogate DNA bind-
ing by 3 H9 anti-DNA autoantibodies, supports the idea that
a number of mutated cases avoid autoreactivity by somatic
mutations [67, 80, 89, 90]. Even so, in the periphery, the
expressed light chain may also be inactivated by somatic
mutation, and an autoreactive light chain can be re-expressed
[91]. It is even possible that an editing event may occur in
peripheral mature B cells, and may produce de novo autoreac-
tive specificity. Fascinatingly, in five of six CLL samples
lacking Ig heavy-chain allelic exclusion, approximately one
of the two heavy-chain rearrangements could be considered
unmutated [66]. Conceivably, these CLL samples undergo an
editing in the heavy chain to avoid self-reactivity. Moreover,
the authors suggest that the allele with somatic mutations had
undergone rearrangement first and was expressed by the B cell
clone during an antigen-driven immune response [66]. Bias in
the usage of the VH3-21 gene has been reported in both
unmutated and mutated CLL B cells, often in combination
with lambda light chains and selected variable lambda genes
[92]. Interestingly, “one mutated VH3-21-using case displayed
double rearrangements with one functional VH4-61 gene rear-
rangement but a nonfunctional VH3-21 gene rearrangement
with a stop codon introduced in the CDR3” [92]. This indicates
that if their original Ig receptor develops enhanced binding
activity for self-antigens through somatic mutation [93, 94],
the B cell might rearrange the other heavy-chain allele to avoid
autoreactivity.
This suggests that mutated CLL B cells might arise
because of somatic mutation during germinal center reac-
tions, and try to avoid autoreactivity through a receptor
editing/revision process. For these reasons, it is possible that
autoreactivity could be avoided in mutated cases by receptor
editing/revision and not only by somatic mutations.
In summary, it is possible that CLL cells avoid the initial
machinery of central tolerance and, despite undergoing a
receptor editing process, both mutated and unmutated CLL
cells maintain a self-reactive BCR and progress to transi-
tional and mature B cells [12, 22]. These details support the
concept proposed by Chiorazzi, according to which CLL is
a clonal disease of B lymphocytes with receptors that vary in
specificity for autoantigens [95].
Anergy is another important mechanism to maintain toler-
ance. There are many self-antigens that are not encountered by
the developing B cell population or that do not have the
capacity to cross-link BCRs to a sufficient degree to elicit the
receptor editing/clonal elimination process. Such cells, even
whenmature, may nonetheless be inactivated through a process
that involves the cross-linking of receptors without the recep-
tion of critical costimulatory signals. These inactivated cells
may be retained in the body but are unresponsive to antigens
and are referred to as anergic. Importantly, when removed from
the presence of the anergy-inducing stimulus, anergic cells may
regain responsiveness. Notably, an anergic B cell population
has been identified in humans.[96] The CLL cells characteris-
tically express low levels of surface Ig, and this fact has been
considered to be an indication that the leukemic cell has been
anergised, probably by exposure to antigens [68, 69]. Remark-
ably, repetitive BCR stimulation of normal B cells leads to
anergy and CD5 expression, both of which are features of CLL.
Importantly, anergy could diminish the lifespan of aner-
gised B cells if they do not receive other survival signals
[97–99]. It is interesting to note that the impairment of
anergic B cell activation appears to be at the level of BCR
signaling, because the activation of proliferation through
either CD40 or TLR is unaffected in the absence of antigens.
Clonal anergy could be involved in both central tolerance
in the bone marrow and peripheral tolerance in the spleen
and lymph nodes. For this reason, we believe that it could be
involved in both mutated and unmutated CLL subsets.
Muzio et al. showed that CLL B cells that do not respond
to BCR ligation (typically belonging to the mutated CLL
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subset) show activation of cellular pathways which suggests
anergy [70]. In general, BCR ligation in the unmutated CLL
subset leads to predominantly activating and proliferative
responses, whereas BCR signaling in the mutated CLL
subset favors anergic and antiapoptotic responses [63, 100,
101]. Intriguingly, the differences in BCR responses in both
subsets might be influenced by disturbances in CD5 expres-
sion and function. CD5 protects from autoimmunity by
several mechanisms that include the inhibition of BCR early
signaling events [34], maintains tolerance in anergic B cells
[28], and induces the secretion of IL-10 in B cells [29].
Unfortunately, in some cases CD5 does not properly inhibit
BCR-mediated signaling in CLL B cells [71]. Disturbances
in CD5+ function have been detected in subsets of patients with
CLL. Significantly, CD5 does not regulate the signaling trig-
gered through BCR in B cells from a subset of B-CLL patients
[71], provides viability signals to B-CLL cells [72, 73], pro-
motes IL-10 secretion in CLL-B cells [74], and protects from
apoptosis [75].
Importantly, sustained or repetitive BCR signaling pro-
motes survival in CLL cells [102, 103]. A significant corre-
lation has been reported between the polyreactivity of the
BCR and an aggressive clinical course of the disease [76].
This aggressive clinical course was even more pronounced
when patients with CLL had BCRs that recognized ≥5
epitopes (“multireactive BCRs”), suggesting that BCRs that
react with various epitopes may be more prone to sustained
signaling [76].
Experimental evidence, combined with clinical observa-
tions such as the fact that the transformation of CLL to large
cell lymphoma (Richter’s Syndrome) and the progression
toward a more malignant phase of the disease characterized
by an increased number of prolymphocytes is often associ-
ated with immunophenotypic drift where CD5 is lost, sup-
ports the notion that CD5 is important in CLL development
and proliferation.
The fact that unmutated and mutated CLL cells derive
from self-reactive precursors [61], the suggestion that CLL
cells are in active (auto)antigen-driven receptor editing [64],
autocrine IL-10 secretion during CD5+ stimulation in leu-
kemic CLL B cells [72, 74], and that most if not all cases of
CLL involve the production of polyreactive monoclonal
antibodies that react with several types of autoantigens,
support the idea that CD5 expression in CLL might be
related to the control of autoimmunity. For these reasons, we
believe that CLL leukemic cells take advantage of impaired
anergy, CD5 expression and IL-10 secretion in some cases. In
summary, anergy could be important to maintain a more
benign disease in mutated CLL B cells; however, the unmu-
tated subset appears to be more resistant to this tolerance
mechanism.
As a final point, in vivo multiple structurally divergent
antigens can bind and stimulate CLL B cells through the
BCR. This fact suggests that these cells could feature a
cross-reactive BCR that recognizes both self- and foreign
antigens generated during an immune response against for-
eign antigens. This could explain the fact that mutated non-
autoreactive CLL antibody sequences reverted in vitro to
their germline counterparts encode polyreactive and autor-
eactive antibodies [61]. In addition, not all autoantigen-
binding BCRs are necessarily detrimental to the organism.
A proportion of BCRs may bind autoantigens with too low
an affinity to trigger an autoimmune response, but may bind
strongly enough to invading pathogens to exert a protective
host-defense effect. Importantly, several BCRs in CLL
clones that bind apoptotic cells and self-structures also bind
epitopes expressed on the coat of common bacteria [95,
104–106]. Some of these CLL clones are from the mutated
CLL subset. Interestingly, the development of CLL shortly
after bacterial pulmonary infections and some common
community-acquired infections has been reported [107,
108]. Current data support the idea that the mutated B cell
subset could derive from self-reactive B cells that have lost
their self-reactivity when passing through the germinal center
reaction by somatic hypermutation [61, 67]. However, some
CLL cells expressing mutated or borderline mutated IGVH
genes could recognize autoantigens [61, 62, 104, 105], thus
advocating the fact that self-reactivity or polyreactivity may
be acquired during somatic hypermutation or that an autor-
eactive B cell passes several tolerance checkpoints. Neverthe-
less, the immune system somehow turns these cells into
“anergic-memory B cells” that cannot produce high-affinity
autoantibodies. This implies that not all autoreactivity is cor-
rected by somatic hypermutation.
Hypothesis about the development of CLL B cells
through tolerance mechanisms
The observation that mutated and unmutated subsets of CLL
have distinct clinical courses is consistent with a two-cell
origin model; however, the homogeneous gene expression
signature, with only minor differences between unmutated
and mutated CLL, suggests a singular originating cell and
the one-cell model.
We propose an alternative theory in that an “original
autoreactive B cell” (unmutated) or a “de novo autoreactive
B cell” (mutated) undergo the same tolerance mechanisms
either in the bone marrow (central) or in the periphery
(lymph nodes), leading to homogenous gene expression.
On the one hand, in this theory, original autoreactive B cells
(unmutated) undergo receptor editing, anergy, and CD5
expression without success, leading to unmutated CLL cells
with autoreactivity, retention of signaling through BCRs and
poor prognosis (Fig. 1). On the other hand, a normal B cell
that acquires autoreactivity during a somatic hypermutation
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process successfully undergoes receptor revision, anergy,
CD5 expression and possible germinal center exclusion,
leading to mutated CLL cells without autoreactivity or
anergy, and only with self-renewing, low/absent BCR
signaling and good prognosis (Fig. 2). Variations of this
theory have been proposed to explain other CD5+ B
cell lymphomas [109].
All in all, we suggest that rather than having a cellular
origin or cellular subtype like marginal zone B cells [42],
CLL is originated by a coordinated normal immunologic
tolerance mechanism to destroy self-reactive B cells and to
avoid autoimmunity. This hypothesis is supported by several
lines of experimental evidence. CLL development might be
influenced by autoantigen recognition in both mutated and
unmutated subsets, and IGVH gene usage is often associated
with autoantibody reactivity [42, 61, 65, 83].
Intriguingly, receptor editing and receptor revision may have
undesirable consequences. For instance, receptor editing may
not always correct autoreactivity, and in the case of VH replace-
ment, the retention of much of the CDR3 may preserve some of
the autoreactivity. In addition, VH replacement antibodies will
usually have longer CDR3, which in itself may predispose them
to auto- or poly-reactivity. Likewise, light-chain editing, while
more frequent than heavy-chain editing andmore likely to occur
at a time when BCR specificity is being tested, does not neces-
sarily result in the correction of autoreactivity.
Based on HCDR3 length, both CLL subsets can express
unusually long HCDR3 [65], suggesting that CLL cells
undergo receptor revision and editing during their develop-
ment [64]. Importantly, the polyreactive binding activity of
natural antibodies may be dependent on somatically-
generated CDR3. Moreover, despite the expression of the
CD27 surface marker, unmutated Ig sequences have been
observed in healthy and rheumatoid arthritis patients,
suggesting that these cells may still be under a diversi-
fication process [110]. We speculate that this diversifi-
cation process could indeed consist in receptor editing
or revision to avoid autoimmunity. Importantly, this
could at least in part explain a proportion of unmutated,
CD5+ CLL clones with unusually long HCDR3 that
express CD27 as well, a “marker of marginal zone B
cells, and memory B cells”.
Anergic B cells are characterized by chronic, low-level
BCR signaling. They also exhibit reduced surface IgM
levels, but can express high levels of IgD. The low expres-
sion of BCR is the hallmark of CLL and anergic B cells.
Interestingly, an in vitro analysis of signal competence
reveals that unmutated CLL cells generally continue to
respond, whereas mutated CLL cells are anergised [63].
CD5 expression protects B lymphocytes from uncontrolled
self-reactivity by increasing the BCR signaling threshold;
however, CD5 does not properly inhibit BCR-mediated
signaling in CLL B cells [72]. In addition, CD5+ can also
promote the autocrine production of IL-10 [71, 72]. Inter-
estingly, these mechanisms could promote the release of
regulatory IL-10 [111], thereby fostering the generation of
B cells [69], with the subsequent capacity to induce an
infectious tolerance and block T cell immune responses
[112].
Importantly, mechanisms meant to increase diversity and
tolerance, like somatic hypermutation or receptor editing/
revision, respectively, could generate double-stranded DNA
breaks, and DNA repair enzymes could, in theory, generate
both translocations and deletions. It is possible that an
autoreactive cell that repeatedly goes through tolerance
checkpoints develops a clonal evolution with acquisitions
of translocations like t(11:14) in mantle cell lymphoma or
13q, 11q, or 17p deletions in CLL.
Fig. 1 Hypothetical
immunologic mechanisms
implicated in the unmutated
CLL subset. The unmutated
CLL subset might derive from
any (non-lineage specific)
autoreactive B cell that
experience several tolerance
mechanisms and are chronically
under check by the persistence
of autoantigens. The cell
surface markers and gene
expression of CLL cells could
simply be the result of several
immunologic mechanisms that
try to destroy or avoid the
persistence of self-reactive B
cells; these mechanisms include
receptor editing, anergy, clonal
deletion, receptor revision, CD5+
expression, germinal center ex-
clusion, and memory B cell check
points
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Additionally, monoclonal B cell lymphocytosis or regula-
tory B cells [69] could also result from these immunological
tolerance mechanisms.
This theory could explain the origin of the cell surface
marker phenotype of CLL (CD5+CD23+CD27+low Igs)
and suggests that both mutated and unmutated cases show
homogenous gene expression signatures, with only minor
differences because both subsets undergo the same tolero-
genic mechanisms. Differences in the “success” of this
tolerance mechanism could be behind the great variety of
clinical presentations in patients with CLL.
Other immunological alterations that might theoretically
predispose to the loss of CLL clone control
Deficiency in self-antigen retention induced by defects in
complement components or impaired clearance of apoptotic
B cells could possibly lead to an increased release of self-
reactive B cells from bone marrow to periphery. On the one
hand, defects in the complement system might cause a
deficient presentation of antigens in the bone marrow and
diminish the protection of the receptor editing mechanism.
On the other hand, impaired clearance of apoptotic cells in
the bone marrow induces an increased stimulation of immature,
self-reactive B cells that could undergo sustained receptor edit-
ing in the bone marrow or avoid tolerance. Importantly, receptor
editing can also produce polyreactive B cells or a simple change
in recognition from an autoantigen to another that recognizes the
newly-edited BCR in an immature B cell. These two mecha-
nisms could be involved in the generation of mantle cell lym-
phoma [109] or CLL with unmutated IGHV genes [64].
Patients with CLL have several disturbances in the com-
plement system [113–115]. Abnormalities in C4 could be
present at several stages of the disease; vice versa, C1q deficien-
cy is restricted to more advanced stages [115]. Interestingly,
abnormalities in the complement system have been associated
with predisposition to both infections and autoimmunity
Fig. 2 Hypothetical immunologic mechanisms implicated in the mu-
tated CLL subset. The mutated CLL subset might derive from any B
cells that acquire “de novo self-reactivity” while undergoing the so-
matic hypermutation process. Following this “de novo auto-reactivity”
development, a normal CD5- B cell can theoretically be transformed
into a “de novo auto-reactive” memory B cell that expresses CD5
(increasing the threshold for BCR activation), undergoes receptor
revision (changing light chain to evade autoimmunity), down-
regulates surface Ig (to avoid activation), and remains under check
by germinal center exclusion (to diminish the chance to progress in the
maturation and become plasma cell). Finally, all these tolerance mech-
anisms converts the CD5- B cell into an “anergic-edited, CD5+CD27+
memory B cell” excluded from germinal centres
Ann Hematol (2012) 91:981–996 989
[116]. An interesting point of view is that low levels of
complement could result in a loss of central tolerance in
the bone marrow, leading to the emergence of autoreactive
clones and predisposing to autoimmunity [117–119],
especially autoimmune haemolytic anemia and immune
thrombocytopenia.
It is remarkable that almost nothing is known about the
autoantigen-presenting modes that establish central B cell
tolerance. However, genetic deficiencies in the complement
components C1q and C4 or secreted natural serum IgM lead
to systemic autoimmune diseases. Two models have been
proposed to explain the emergence of autoantigen-reactive
B cells. In one model, macrophages expressing the appro-
priate complement receptors (C1qR and CR1) efficiently
remove apoptotic cells that are bound by natural IgM, C1q
and C4b, thereby preventing the accumulation of these cells
and subsequent activation of mature B cells [117]. The other
model suggests that autoantigens from apoptotic cells are
presented to immature B cells by immune complexes con-
taining C1q, C4b, and IgM on a yet unidentified cell
expressing the appropriate receptors C1qR, CR1, and possibly
FcRμ. In the latter model, this antigen presentation can result
in negative selection and/or anergy [120]. A better under-
standing of the modes of central tolerance induced by apopto-
sis, editing, anergy and ignorance requires the identification of
relevant antigen-presenting cell populations. Despite this,
some authorities on CLL suggest that CLL cells themselves
“once they undergo apoptosis within infiltrated peripheral
tissues” might be involved in self-perpetuating the disease
by providing autoantigenic targets [121]. In support of
this model, Tripodo et al. discovered C1q production by
bone marrow stromal cells, an important part of com-
plement that is involved in the clearance of apoptotic
cells [122]. Defects in complement, bone marrow infil-
tration, the high frequency of self-reactive/polyreactive
CLL B cells, and the increased presence of autoimmune
phenomena in advanced stages of CLL suggest that it is
possible that apoptotic cells in this compartment play an
active role in disease progression.
How are complement and immunoglobulin deficiencies
related to the processes that lead to CLL development?
Molecular motifs exposed on the surface blebs of
apoptotic cells or microbial epitopes expressed on the
surface coat of common bacteria may be relevant in triggering
and/or facilitating the evolution of CLL [105, 123]. This is
important because the impaired clearance of autoantigens or
the presence of bacterial antigens that mimic self-structures
could contribute to increasing antigen-driven proliferation of
CLL B cells.
Apoptotic cells are recognized by multiple receptors,
including complement C3 and C1q fractions, as well as
natural autoantibodies (IgM) [124–126]. Natural IgM auto-
antibodies bind to phospholipids exposed on apoptotic cells
and also activate the classical pathway, generating C1q,
C4b, C3b, and iC3b ligands for complement receptors.
Phagocytosis of apoptotic cells generally induces anti-
Fig. 3 The role of complement
in apoptotic cell recognition
and prevention of
autoimmunity. Complement
binding to immune complexes
or to auto-antigens protects
from autoimmunity by enhanc-
ing presentation of antigens to
self-reactive B cells at an im-
mature stage. Phagocytosis of
apoptotic cells generally indu-
ces the release of anti-
inflammatory cytokines
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inflammatory cytokines such as transforming growth factor B
and IL-10 [124, 125] (Fig. 3). The association between comple-
ment or immunoglobulin deficiencies and CLL could be attrib-
uted to a failure of complement-dependent opsonization,
resulting in an accumulation of apoptotic cells and a release of
autoantigens that constitute a continuous stimulus for CLL clone
proliferation (Fig. 3).
An overall reduction in antibody production can also
contribute to the inability to eradicate microbial pathogens
with structures similar to autoantigens, which leads to
chronic stimulation for the CLL clone.
Moreover, complement binding to immune complexes or
to autoantigens could protect from autoimmunity by enhancing
the presentation of antigens to self-reactive B cells at the imma-
ture stage or in the T1–T2 transitional stages [127] (Fig. 3).
Complement deficiencies and low levels of immunoglobulins
observed in CLL could contribute to impaired retention of
self-antigens bound to complement and/or antibodies (im-
mune complexes) in the bone marrow and spleen, having a
negative impact on central tolerance mechanisms and contrib-
uting to the selection of autoreactive clones that are related or
unrelated to CLL (Fig. 4).
Fig. 4 Complement
deficiencies and low levels of
immunoglobulins observed in
CLL could contribute to
autoimmunity
Fig. 5 Infectious tolerance
induced by CLL-B cells
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This could explain why autoantibodies causing autoimmune
thrombocytopenia and hemolytic anemia are produced by resid-
ual normal B cells in CLL patients. The mechanisms of hema-
tological autoimmunity in CLL could be similar to those
observed in common variable immunodeficiency (CVID)
patients [128].
CLL disease-associated immunosuppression
IL-10 is a potent inducer of B lymphocyte differentiation as
well as an inhibitor of T cell lymphocytes and antigen-
presenting cells [129]. Autocrine IL-10 is produced by
autoreactive (systemic lupus erythematosus SLE) [130,
131] and immature CD5+ B cells [132]. Significantly, IL-
10 could protect from apoptosis and induce the expression
of BCL-2 in B cells [129]. Notably, CD5 provides viability
signals and leads to IL-10 production, which acts as an
autocrine growth factor for leukemic B cells [72]. However,
CD5 does not properly inhibit BCR-mediated signaling in
CLL B cells [71]. It is possible that autoantigen stimulation
through BCR in an autoreactive B cell guide the expression
of CD5+ by increasing the threshold for BCR activation to
avoid the process leading to antibody production. Moreover,
it could also induce the autocrine production of IL-10 to
down-regulate costimulatory molecules like CD80, thus
promoting an immunosuppressive microenvironment that
blocks the activation of T and antigen-presenting cells to
avoid autoimmunity. In CLL, this mechanism might induce
a process known as infectious tolerance [133] in cell–cell
contact, mediated by autocrine IL-10, in a similar manner to
regulatory T [134] or B cells [135, 136]. If these autoreac-
tive B cells persist and proliferate by autoantigenic stimulus,
presumably a persistent T cell inhibition could be main-
tained in a straight line with the load of autoreactive CD5+
and IL-10+ B cells. This hypothesis could explain the exis-
tence of defective synapses in CLL (Fig. 5).
Still, open questions are: then, why and when a B cell
expresses CD5 antigen and produces autocrine IL-10 as it
comes to recognize an autoantigen. The answer could be
that during the tolerance process in bone marrow or during
somatic hypermutation, B cells must be disconnected from
Tcells, since autoimmunity could be corrected (receptor editing)
or abrogated (anergy or deletion). The migration of immature T
cells from the bone marrow to the thymus reduces the opportu-
nity to interact with immature B cells. In a germinal centre, if a B
cell becomes self-reactive, it could be excluded or tolerized in
the absence of T cell help (deletion of autoreactive T cells
specific for an autoantigen in the thymus). Interestingly, IL-10-
producing regulatory B cells are enriched in both memory
(CD27+) and transitional (CD38high) B cell compartment
[135]. We hypothesize that CLL leukemic B cells could repre-
sent a self-reactive (e.g., CD5+ expression and autoreactive-
related usage of IGHV) regulatory B cell (e.g., production of
IL-10, exspression of CD27) clone that is driven to proliferate
by the common environment and the autoantigens that they
recognize. This mechanism could support the previous sugges-
tion that CLL cells might behave like regulatory B cells [69].
Conclusion
Stem cells from patients with CLL produce an increased
amount of pro-B cells. These pro-B cells undergo tolerance
in bone marrow stroma and the peripheral lymphatic system.
We suggest that during several stages of B cell development
CLL B cell clones might emerge when self-reactive B cells
undergo receptor editing/revision, anergy, CD5+ expression
and somatic hypermutation. CLL is a proliferation of B
lymphocytes selected from clonal expansion through multi-
ple encounters with (auto)antigens, despite the fact that they
differ in their state of activation and maturation. Autoanti-
gens and microbial pathogens activate BCR signaling and
promote tolerogenic mechanisms such as receptor editing/
revision, anergy, CD5+ expression and somatic hypermuta-
tion in CLL B cells. These mechanisms support the gener-
ation of new poly-reactive or oligo-reactive BCRs in
unmutated or mutated CLL B cell subsets, respectively.
Autocrine immunosuppressive cytokines produced by CLL
B cell clones can help to produce defects in T cells. Survival
of CLL B cell clones with similar surface markers and
homogeneous gene expression signatures that is with only
minor overall differences, might be a sign of several
attempts to re-educate self-reactive B cells. It is possible
that self-reactive B cells that are repeatedly exposed to
tolerance checkpoints develop a clonal evolution with
acquisitions of surface markers and deletions like 13q,
11q, or 17p that are associated with CLL.
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